A history of Panton-Valentine leukocidin (PVL)-associated infection protects against death in PVL-associated pneumonia

Vaccine

Volumn 29, Issue 25, 2011, Pages 4185-4186

  Rasigade, Jean Philippe ^a   Sicot, Nicolas ^a   Laurent, Frederic ^a   Lina, Gerard ^a   Vandenesch, François ^a   Etienne, Jerome ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

Neutralizing antibody; Panton Valentine leukocidin; Staphylococcal pneumonia; Staphylococcal skin infection; Staphylococcus aureus

Indexed keywords

INOTROPIC AGENT; NEUTRALIZING ANTIBODY; PANTON VALENTINE LEUKOCIDIN;

ANAMNESIS; ANTIBODY PRODUCTION; ARTICLE; ARTIFICIAL VENTILATION; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; FURUNCULOSIS; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

BACTERIAL TOXINS; EXOTOXINS; HUMANS; LEUKOCIDINS; PNEUMONIA, STAPHYLOCOCCAL; PREVALENCE; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCUS AUREUS; VIRULENCE FACTORS;

EID: 79956227197     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.033     Document Type: Article

References (9)

1. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298(15):1763-1771.
2. Tristan A., Bes M., Meugnier H., Lina G., Bozdogan B., Courvalin P., et al. Global distribution of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus, 2006. Emerg Infect Dis 2007, 13(4):594-600.
3. Otto M. Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu Rev Microbiol 2010, 64:143-162.
4. ClinicalTrials.gov. Staphylococcus aureus toxoids phase 1-2 vaccine trial. [accessed 01.01.11]. http://www.clinicaltrials.gov/ct2/show/NCT01011335?term=NABI&rank5.
5. Hermos C.R., Yoong P., Pier G.B. High levels of antibody to Panton-Valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection. Clin Infect Dis 2010, 51(10):1138-1146.
6. Yoong P., Pier G.B. Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci USA 2010, 107(5):2241-2246.
7. Masiuk H, Kopron K., Grumann D., Goerke C., Kolata J., Jursa-Kulesza J., et al. Association of recurrent furunculosis with Panton-Valentine leukocidin and the genetic background of Staphylococcus aureus. J Clin Microbiol 2010, 48(5):1527-1535.
8. Brown E.L., Dumitrescu O., Thomas D., Badiou C., Koers E.M., Choudhury P., et al. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infect 2009, 15(2):156-164.
9. Gillet Y., Vanhems P., Lina G., Bes M., Vandenesch F., Floret D., et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007, 45(3):315-321.